证券代码：600422 证券简称：昆药集团 公告编号：2025-063 号 昆药集团股份有限公司 2025年第五次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 12 月 29 日 (二)股东大会召开的地点：云南省昆明市国家高新技术开发区科医路 166 号昆药 集团股份有限公司管理中心 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 288 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 311,589,444 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 41.1624 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议的召集、召开程序符合《中华人民共和国公司法》《上市公司股东 会规则》（下称"《股东会规则》" ...

北京德恒（昆明）律师事务所 关于昆药集团股份有限公司 2025 年第五次临时股东会的 法律意见 北京德恒（昆明）律师事务所 Beijing DeHeng Law Offices (KunMing) 云南省昆明市西山区西园路 126 号"融城优郡"B5 幢 3、4 层 电话（传真）：0871-63172192 邮编: 650032 北京德恒（昆明）律师事务所 关于昆药集团股份有限公司 2025 年第五次临时股东会的法律意见 北京德恒（昆明）律师事务所 关于昆药集团股份有限公司 2025 年第五次临时股东会的 法 律 意 见 昆药集团股份有限公司： 北京德恒（昆明）律师事务所（下称"本所"）作为贵公司的常年法律顾问， 本次指派刘书含律师、李妍律师出席贵公司 2025 年第五次临时股东会（以下简 称"本次股东会"），并按照律师行业公认的业务标准、道德规范及勤勉尽责精 神，对贵公司提供的与本次股东会有关的文件资料进行了审查，现根据《公司法》 《证券法》《上市公司股东会规则》及贵公司《章程》的规定，就贵公司本次股 东会的相关事项出具如下法律意见： 一、关于本次股东会的召集和召开程序 根据贵公司提供的有关资料及公开披露的 ...

债 券 周 评 相关研究 证 券 研 究 报 告 证券分析师 黄伟平 A0230524110002 huangwp@swsresearch.com 王明路 A0230525060003 wangml@swsresearch.com 徐亚 A0230524060002 xuya@swsresearch.com 联系人 徐亚 A0230524060002 xuya@swsresearch.com 2025 年 12 月 27 日 主题风格活跃，高价券领涨 ——转债周度跟踪 20251226 ⚫ 1. 周观点及展望 ⚫ 本周中证 2000 领涨，微盘股延续修复，转债风格适配、明显跟涨，商业航天概念持续火 热带动军工板块表现亮眼，金融、消费等临期大盘转债依旧承压，加之强赎风险阶段性回 落，偏股转债受益于平价和估值双击，涨幅明显好于大盘偏债转债。在经历强势修复后， 转债重回前期高点，主要表现为百元溢价率、转债价格中位数等均距离前期高点"一步之 遥"。但与 11 月上旬的修复行情相比，本轮表现较强的主要是偏股型高价转债，而 11 月 上旬则是偏债型低价转债较强，因此本轮强势修复后转债弹性要强于前期，虽然回撤会同 步放大， ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： ●被担保人：贝克诺顿（浙江）制药有限公司（以下简称"贝克浙江"）、昆药商业（昭通）医药有限公 司（以下简称"昭通医药"）。上述被担保人分别为华润三九医药股份有限公司（以下简称"华润三九"） 控股子公司昆药集团股份有限公司（以下简称"昆药集团"）下属全资子公司昆明贝克诺顿制药有限公司 （以下简称"贝克制药"）、昆药集团医药商业有限公司（以下简称"昆药商业"）的全资子公司，不存在 关联担保。 ●本次担保金额及已实际为其提供的担保余额：本次为上述被担保人提供的担保金额为1,000万元，累计 已实际为其提供的担保余额为1,500万元。 ●特别风险提示：本次被担保人昭通医药为资产负债率超过70%的公司，敬请投资者注意相关风险。 ■ 以上被担保人，信用状况良好，不属于失信被执行人，列示财务状况为被担保人公司单体数据。 ●是否在前期预计额度内：是 ●本次担保是否有反担保：不适用 ●对外担保逾期的累计数量：无 二、被担保公司情况 （一）基本情况 1、贝克诺顿（浙江 ...

证券代码：600422 证券简称：昆药集团 公告编号：2025-062号 昆药集团股份有限公司关于对外担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、担保情况概述 （一）内部决策程序 为支持公司旗下全资及控股子公司2025年生产经营及业务发展需要，满足相关下属公司融资担保需求， 经公司十一届三次董事会及2025年第三次临时股东大会审议通过，2025年度由公司及下属子公司为旗下 公司合计不超过人民币4.5615亿元的银行融资授信业务提供连带责任担保，详见《昆药集团股份有限公 司关于2025年度担保计划的公告》（2025-020号）和《昆药集团股份有限公司2025年第三次临时股东大 会决议公告》（2025-026号）。 （二）担保的基本情况 重要内容提示： ● 担保对象及基本情况 ■ 注：上述被担保人为昆药集团股份有限公司（以下简称"本公司"、"公司" 或"昆药集团"）的全资子公司 昆明贝克诺顿制药有限公司（以下简称"贝克制药"）的全资子公司，及公司下属全资子公司昆药集团医 药商业有限公司（以下简称"昆药商业" ...

证券代码：600422 证券简称：昆药集团 公告编号：2025-062 号 昆药集团股份有限公司关于对外担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | | 贝克诺顿（浙江）制药有限公司（以下简称"贝 | | --- | --- | --- | --- | --- | | | | 克浙江"） | | | | | 本次担保金额 | 万元 500 | | | | 担保对象一 | 实际为其提供的担保余额 | 500 万元 | | | | | 是否在前期预计额度内 | 是 | □否 | □ 不适用：_________ | | | 本次担保是否有反担保 | □是 | □否 | 不适用：_________ | | 担保对象二 | 被担保人名称 | 通医药"） | | 昆药商业（昭通）医药有限公司（以下简称"昭 | | | 本次担保金额 | 500 | 万元 | | | | 实际为其提供的担保余额 | 1,000 | 万元 | | | | 是否在前期预计额度 ...

昆药集团股份有限公司 KPC Pharmaceuticals, Inc. 2025 年第五次临时股东大会 会 议 资 料 股票简称：昆药集团 股票代码：600422 2025 年 12 月 2025 年第五次临时股东大会会议资料 会 议 须 知 为适应上市公司规范运作，提高股东大会议事效率，保障股东合法权益，确保大 会程序合法性，根据《中华人民共和国公司法》《中华人民共和国证券法》《公司章 程》以及《公司股东大会议事规则》等精神，特制定如下大会须知，望出席昆药集团 股份有限公司（以下简称"昆药集团"或"公司"）股东大会的全体人员严格遵守： 一、本次股东大会由公司董事会办公室具体负责大会的组织工作。 二、董事会以维护股东的合法权益，确保大会正常秩序和议事效率为原则，认真 履行法定职责。 三、出席本次股东大会的股东，依法享有发言权、表决权等各项权利。 四、会议期间请保持会场纪律、严肃对待每一项议题，会议期间全过程录音。 五、股东及股东代表参加本次股东大会，应当认真履行法定义务，不得侵犯其他 股东的权益，不得扰乱大会的正常程序和会议秩序。 六、会议议题全部说明完毕后统一审议、统一表决；股东大会采取现场投票和网 络投 ...

Core Viewpoint - The nylon industry in Pingdingshan is rapidly developing, with significant investments and projects aimed at transforming the city from a coal-dependent economy to a diversified nylon materials hub [5][7][15]. Industry Development - The second China Nylon Industry Development Conference was held in late November, attracting major textile and apparel companies, indicating strong interest and investment in the nylon sector [5]. - Pingdingshan has accelerated its nylon industry development, with over 200 enterprises and projects established, and nylon-related production capacity exceeding 4 million tons [7][8]. Strategic Initiatives - The city is implementing four major strategies: "Big Nylon, Full Industry Chain, Internationalization, and Innovation Leadership," to enhance its nylon industry [7]. - A total of 74 nylon new material projects have been initiated this year, with a total investment of 53.722 billion yuan, including 30 new projects and 12 ongoing projects [8]. Innovation and Technology - The first domestic 100,000 tons/year nylon 66 production facility was launched by Pingdingshan Coal and Chemical Group, marking a significant breakthrough in securing the nylon supply chain [10]. - The city has supported 37 major technology projects through provincial industry joint research funds, focusing on clean and efficient utilization of coal tar [11]. Infrastructure and Support - Pingdingshan is enhancing its infrastructure to support the nylon industry, including the establishment of a national-level "Green Chemical Park" and significant reductions in industrial electricity costs [12][13]. - The city has set up two major funds to support the development of nylon new materials and green industries, providing financial backing for key projects [13]. Open Development - The opening of Pingdingshan Port enhances water transport capabilities, facilitating the movement of goods and integration into national markets [14]. - The city is improving its land transport network, including high-speed rail and highways, to ensure seamless logistics for the nylon industry [14]. Future Outlook - Over the next five years, Pingdingshan plans to invest over 80 billion yuan in key nylon new material projects, aiming for significant growth and competitiveness in the global market by 2030 [15].

Core Insights - The event showcased China Resources Sanjiu's commitment to public health and its brand vision of "Caring for Public Health and Creating a Better Life" through an innovative dual venue model [2][4] - The activities attracted a wide range of participants, including group leaders, industry guests, media representatives, and employees, creating a vibrant atmosphere [2] Group 1: Brand Presentation - China Resources Sanjiu highlighted its core brand values by showcasing four major brands: 999, Tianshili, Kunming Pharmaceutical Group, and China Resources Tang [2] - The event featured well-known products such as 999 Cold Medicine and Tianshili's cardiovascular formulations, covering essential household medications and health products [2] - Interactive experiences, such as the intestinal maze game and herbal tea tastings, allowed attendees to engage with health knowledge in a fun way [2][3] Group 2: Headquarters Market - The headquarters market emphasized immersive experiences and emotional connections with media guests and surrounding communities through six unique booths [3] - Each booth offered distinct experiences, such as traditional craftsmanship combined with health products, DIY herbal sachets, and interactive games focused on gastrointestinal health [3] - The event reinforced brand memory through the "San Jiu" IP, encouraging participants to engage with the brand for customized rewards [3][4] Group 3: Brand Communication and Future Plans - The dual venue market event was an innovative attempt to communicate the brand's health philosophy and strengthen internal cohesion and community connections [4] - China Resources Sanjiu aims to continue focusing on consumer needs by organizing diverse and relatable brand activities to promote health concepts [4] - The successful execution of the brand day event enriched the format of the group's activities and deepened the brand image of "Warm Guardian" [4]

Core Viewpoint - The article emphasizes the significant market potential for insomnia treatment, highlighting the promising sales performance of newly listed drugs in this sector [16][22][24]. Market Overview - The current insomnia medication market in China is estimated at 31.62 billion yuan, with a large unmet demand due to existing medications failing to meet treatment needs [26]. - The proportion of individuals experiencing insomnia symptoms in China is reported at 16.8%, indicating a potential patient population exceeding 200 million [20][31]. Drug Development and Innovation - The development of insomnia medications has evolved through four generations, with the latest focusing on physiological regulation rather than merely sedative effects [21][32]. - New insomnia drugs, particularly novel benzodiazepine receptor agonists (BZRAs) and dual orexin receptor antagonists (DORAs), are gaining traction, with several products recently launched [24][34]. Specific Drug Insights - The newly launched drug, Dazadiline, is expected to capture a significant market share due to its unique mechanism of action and favorable safety profile, with projected peak sales of 15.6 billion yuan [33]. - Dazadiline's pricing is set at 13.88 yuan per day, making it competitive in the market [33]. - DORAs, such as Daridorexant, are noted for their non-addictive properties and potential for broader consumer acceptance, as they do not fall under strict regulatory controls [38]. Market Dynamics - The article discusses the competitive landscape, noting that the introduction of new insomnia treatments could disrupt the existing market dominated by older, less effective medications [26][27]. - The sales performance of insomnia drugs is expected to improve significantly as new products enter the market and address the needs of a large patient population [16][24]. Future Projections - The article forecasts a steady increase in the number of patients treated for insomnia, with the treatment rate projected to rise from 7.5% in 2024 to 12.1% by 2033 [31]. - The market for insomnia medications is anticipated to grow rapidly, driven by the introduction of innovative therapies and an increasing awareness of sleep health [16][24].